肿瘤指南

订阅

MedSci主页 / 所有栏目 / 肿瘤指南

PARP抑制剂不良反应管理的中国专家共识

2021-11-01 中国抗癌协会妇科肿瘤专业委员会 中国实用妇科与产科杂志

卵巢癌妇科肿瘤PARP抑制剂

卵巢癌是一种常见的妇科恶性肿瘤,我国每年新发病例约5.5万例,每年死亡人数达3.7万例。

中文标题：

PARP抑制剂不良反应管理的中国专家共识

发布机构：

中国抗癌协会妇科肿瘤专业委员会

发布日期：

2021-11-01

简要介绍：

卵巢癌是一种常见的妇科恶性肿瘤,我国每年新发病例约5.5万例,每年死亡人数达3.7万例[1-2]。经传统手术和含铂化疗治疗后,仅40%的患者生存期超过5年[3]。多项研究证实聚腺苷二磷酸核糖聚合酶（poly ADP-ribose poly-merase,PARP）抑制剂维持治疗可以显著延长新诊断或铂敏感复发性卵巢癌患者的生存期,已经成为卵巢癌治疗的新模式。随着PARP抑制剂的广泛应用,药物相关的不良反应也备受关注。PARP抑制剂的不良反应包括血液毒性、消化道毒性、神经毒性等,每种药物还有其特定的毒性反应。管理PARP抑制剂导致的不良反应有助于提高患者药物治疗依从性,进而改善患者的临床结局。 

相关资料下载：
[AttachmentFileName(sort=1, fileName=PARP抑制剂不良反应管理的中国专家共识 2021年版.pdf)] GetToolGuiderByIdResponse(projectId=1, id=8fcc01c002269af7, title=PARP抑制剂不良反应管理的中国专家共识, enTitle=, guiderFrom=中国实用妇科与产科杂志, authorId=0, author=, summary=卵巢癌是一种常见的妇科恶性肿瘤,我国每年新发病例约5.5万例,每年死亡人数达3.7万例。, cover=https://img.medsci.cn/20211122/1637596375431_5579292.jpg, journalId=0, articlesId=null, associationId=1526, associationName=中国抗癌协会妇科肿瘤专业委员会, associationIntro=, copyright=0, guiderPublishedTime=Mon Nov 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #333333;">卵巢癌是一种常见的妇科恶性肿瘤,我国每年新发病例约5.5万例,每年死亡人数达3.7万例</span><sup style="color: #333333;">[1-2]</sup><span style="color: #333333;">。经传统手术和含铂化疗治疗后,仅40%的患者生存期超过5年</span><sup style="color: #333333;">[3]</sup><span style="color: #333333;">。多项研究证实聚腺苷二磷酸核糖聚合酶（poly ADP-ribose poly-merase,PARP）抑制剂维持治疗可以显著延长新诊断或铂敏感复发性卵巢癌患者的生存期,已经成为卵巢癌治疗的新模式。随着PARP抑制剂的广泛应用,药物相关的不良反应也备受关注。PARP抑制剂的不良反应包括血液毒性、消化道毒性、神经毒性等,每种药物还有其特定的毒性反应。管理PARP抑制剂导致的不良反应有助于提高患者药物治疗依从性,进而改善患者的临床结局。&nbsp;</span></p>, tagList=[TagDto(tagId=359, tagName=卵巢癌), TagDto(tagId=1983, tagName=妇科肿瘤), TagDto(tagId=22079, tagName=PARP抑制剂)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=36, categoryName=妇产科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=22079, guiderKeyword=PARP抑制剂, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3529, appHits=147, showAppHits=0, pcHits=582, showPcHits=3382, likes=1, shares=27, comments=10, approvalStatus=1, publishedTime=Tue Nov 23 00:10:04 CST 2021, publishedTimeString=2021-11-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 22 23:56:43 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 18:55:40 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=PARP抑制剂不良反应管理的中国专家共识 2021年版.pdf)])
PARP抑制剂不良反应管理的中国专家共识 2021年版.pdf
下载请点击：
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2104375, encodeId=086d21043e54f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81728464993, createdName=ms2000000753087000, createdTime=Mon Dec 05 11:35:47 CST 2022, time=2022-12-05, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1238082, encodeId=7b5b1238082e1, content=学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGRRYEU0f47iay1YD1icYNstpqX3l0DlJsB59gNc5n0fibxltJTeM7FLRKMlfZ5VmBsvcAra0xdWicnA/132, createdBy=18cf5322661, createdName=武阳, createdTime=Thu Aug 11 16:21:02 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222003, encodeId=f5de1222003e8, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:17:32 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186086, encodeId=6536118608682, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d995020738, createdName=3254357, createdTime=Wed Jan 19 17:45:28 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183476, encodeId=d81b11834e6ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ef82083040, createdName=1391f297e2m, createdTime=Wed Jan 12 10:47:52 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-12-05 ms2000000753087000 来自陕西省

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2104375, encodeId=086d21043e54f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81728464993, createdName=ms2000000753087000, createdTime=Mon Dec 05 11:35:47 CST 2022, time=2022-12-05, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1238082, encodeId=7b5b1238082e1, content=学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGRRYEU0f47iay1YD1icYNstpqX3l0DlJsB59gNc5n0fibxltJTeM7FLRKMlfZ5VmBsvcAra0xdWicnA/132, createdBy=18cf5322661, createdName=武阳, createdTime=Thu Aug 11 16:21:02 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222003, encodeId=f5de1222003e8, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:17:32 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186086, encodeId=6536118608682, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d995020738, createdName=3254357, createdTime=Wed Jan 19 17:45:28 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183476, encodeId=d81b11834e6ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ef82083040, createdName=1391f297e2m, createdTime=Wed Jan 12 10:47:52 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-08-11 武阳

    学习了。

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2104375, encodeId=086d21043e54f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81728464993, createdName=ms2000000753087000, createdTime=Mon Dec 05 11:35:47 CST 2022, time=2022-12-05, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1238082, encodeId=7b5b1238082e1, content=学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGRRYEU0f47iay1YD1icYNstpqX3l0DlJsB59gNc5n0fibxltJTeM7FLRKMlfZ5VmBsvcAra0xdWicnA/132, createdBy=18cf5322661, createdName=武阳, createdTime=Thu Aug 11 16:21:02 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222003, encodeId=f5de1222003e8, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:17:32 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186086, encodeId=6536118608682, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d995020738, createdName=3254357, createdTime=Wed Jan 19 17:45:28 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183476, encodeId=d81b11834e6ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ef82083040, createdName=1391f297e2m, createdTime=Wed Jan 12 10:47:52 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-05-24 清风徐来2022

    #PARP抑制剂#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2104375, encodeId=086d21043e54f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81728464993, createdName=ms2000000753087000, createdTime=Mon Dec 05 11:35:47 CST 2022, time=2022-12-05, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1238082, encodeId=7b5b1238082e1, content=学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGRRYEU0f47iay1YD1icYNstpqX3l0DlJsB59gNc5n0fibxltJTeM7FLRKMlfZ5VmBsvcAra0xdWicnA/132, createdBy=18cf5322661, createdName=武阳, createdTime=Thu Aug 11 16:21:02 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222003, encodeId=f5de1222003e8, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:17:32 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186086, encodeId=6536118608682, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d995020738, createdName=3254357, createdTime=Wed Jan 19 17:45:28 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183476, encodeId=d81b11834e6ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ef82083040, createdName=1391f297e2m, createdTime=Wed Jan 12 10:47:52 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-19 3254357

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2104375, encodeId=086d21043e54f, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81728464993, createdName=ms2000000753087000, createdTime=Mon Dec 05 11:35:47 CST 2022, time=2022-12-05, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=1238082, encodeId=7b5b1238082e1, content=学习了。, beContent=null, objectType=guider, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erGRRYEU0f47iay1YD1icYNstpqX3l0DlJsB59gNc5n0fibxltJTeM7FLRKMlfZ5VmBsvcAra0xdWicnA/132, createdBy=18cf5322661, createdName=武阳, createdTime=Thu Aug 11 16:21:02 CST 2022, time=2022-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1222003, encodeId=f5de1222003e8, content=<a href='/topic/show?id=e08113e613e' target=_blank style='color:#2F92EE;'>#PARP抑制剂#</a>, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13761, encryptionId=e08113e613e, topicName=PARP抑制剂)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=清风徐来2022, createdTime=Tue May 24 11:17:32 CST 2022, time=2022-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186086, encodeId=6536118608682, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d995020738, createdName=3254357, createdTime=Wed Jan 19 17:45:28 CST 2022, time=2022-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1183476, encodeId=d81b11834e6ba, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ef82083040, createdName=1391f297e2m, createdTime=Wed Jan 12 10:47:52 CST 2022, time=2022-01-12, status=1, ipAttribution=)]
    2022-01-12 1391f297e2m

    学习

    0

相关指南

上皮性卵巢癌PARP抑制剂相关生物标志物 检测的中国专家共识 2020

中国抗癌协会(Chinese Anti-cancer Association) · 2021-09-01

2021 ESGO指南：晚期卵巢癌减瘤手术的围术期管理

欧洲妇科肿瘤学会(ESGO,European Society of Gynecological Oncology) · 2021-08-18

晚期上皮性卵巢癌新辅助化疗指征的快速指南（2021年版）

中国医师协会微无创分会乳腺专家委员会 · 2021-04-20

SEOM卵巢癌临床指南 2020

西班牙医学肿瘤学会（ Spanish Society of Medical Oncology） · 2021-02-01

拓展阅读

PARP抑制剂治疗复发性卵巢癌专家共识

妇产科相关专家组（统称） · 2018-10-20

2022 加拿大共识声明：晚期、高级别浆液性和子宫内膜样输卵管癌、卵巢癌和原发性腹膜癌的一线PARP抑制剂维持治疗

国外肿瘤科相关专家小组（统称） · 2022-06-17

卵巢癌PARP抑制剂临床应用指南（2022版）

暂未更新 · 2022-08-08

关于《PARP抑制剂耐药机制及应对策略》的解读

四川大学华西第二医院肿瘤放化疗科 · 2022-09-08

2020 ASCO指南：卵巢癌治疗中的PARP抑制剂

美国临床肿瘤学会(ASCO,American Society of Clinical Oncology) · 2020-12-01

PARP抑制剂在卵巢癌中的应用美国临床肿瘤学会指南快速更新推荐解读

四川大学华西第二医院妇产科出生缺陷与相关妇儿疾病教育部重点实验室 · 2023-01-15